These cells were derived from unaffected tau wild-type (WT) individuals (Control-1, Control-2), from a PSP patient with a tau-A152T risk variant, and from a patient with FTD carrier of a tau-P301L autosomal dominant mutation21,37,38. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.